Pfizer: Sun Setting On Blockbuster Model
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry execs chart move away from “bull’s eye” toward risk sharing.
You may also be interested in...
Personalized Medicine Not A Threat To Blockbuster Model - Lilly President Lechleiter
Pharma has rarely pursued one-size-fits-all strategies, instead segmenting disease categories or patient groups, an effort personalized medicine can only render more relevant and meaningful, exec says.
Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders
Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.
Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal
In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.